References

Abd El Aal, D. E., Mohamed, S. A., Amine, A. F., and Meki, A. R. (2005). Vascular endothelial growth factor and insulin-like growth factor-1 in polycystic ovary syndrome and their relation to ovarian blood flow. Eur. J. Obstet. Gynecol. Reprod. Biol. 118, 219–224.
| CrossRef | CAS | PubMed |

Abramovich, D., Irusta, G., Parborell, F., and Tesone, M. (2010). Intrabursal injection of vascular endothelial growth factor trap in eCG-treated prepubertal rats inhibits proliferation and increases apoptosis of follicular cells involving the PI3K/AKT signalling pathway. Fertil. Steril. 93, 1369–1377.
| CrossRef | CAS | PubMed |

Agrawal, R., Sladkevicius, P., Engmann, L., Conway, G. S., Payne, N. N., Bekis, J., Tan, S. L., Campbell, S., and Jacobs, H. S. (1998). Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries. Hum. Reprod. 13, 651–655.
| CrossRef | CAS | PubMed |

Alvarez, A. A., Axelrod, J. R., Whitaker, R. S., Isner, P. D., Bentley, R. C., Dodge, R. K., and Rodriguez, G. C. (2001). Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumour angiogenesis and survival in platinum-treated patients. Gynecol. Oncol. 82, 273–278.
| CrossRef | CAS | PubMed |

Amin, A. F., Abd el-Aal, D. E., Darwish, A. M., and Meki, A. R. (2003). Evaluation of the impact of laparoscopic ovarian drilling on Doppler indices of ovarian stromal blood flow, serum vascular endothelial growth factor and insulin-like growth factor-1 in women with polycystic ovary syndrome. Fertil. Steril. 79, 938–941.
| CrossRef | PubMed |

Araújo, V. R., Silva, G. M., Duarte, A. B., Magalhães, D. M., Almeida, A. P., Gonçalves, R. F., Bruno, J. B., Silva, T. F., Campello, C. C., Rodrigues, A. P., and Figueiredo, J. R. (2011). Vascular endothelial growth factor-A(165) (VEGF-A(165)) stimulates the in vitro development and oocyte competence of goat preantral follicles. Cell Tissue Res. 346, 273–281.
| CrossRef | PubMed |

Armstrong, L. C., and Bornstein, P. (2003). Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol. 22, 63–71.
| CrossRef | CAS | PubMed |

Badawy, A., and Elnashar, A. (2011). Treatment options for polycystic ovary syndrome. Int. J. Womens Health. 3, 25–35.
| CrossRef | PubMed |

Balasubramanian, R., Plummer, L., Sidis, Y., Pitteloud, N., Martin, C., Zhou, Q. Y., and Crowley, W. F. (2011). The puzzles of the prokineticin 2 pathway in human reproduction. Mol. Cell. Endocrinol. 346, 44–50.
| CrossRef | CAS | PubMed |

Busso, C., Fernández-Sánchez, M., García-Velasco, J. A., Landeras, J., Ballesteros, A., Muñoz, E., González, S., Simón, C., Arce, J. C., and Pellicer, A. (2010). The non-ergot-derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomised, double-blind, placebo-controlled trial. Hum. Reprod. 25, 995–1004.
| CrossRef | CAS | PubMed |

Campbell, N. E., Greenaway, J., Henkin, J., Moorehead, R. A., and Petrik, J. (2010). The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia 12, 275–283.
| CAS | PubMed |

Chen, L., Zhang, J. J., Rafii, S., and Huang, X. Y. (2009). Suppression of tumour angiogenesis by Galpha(13) haploinsufficiency. J. Biol. Chem. 284, 27 409–27 415.
| CrossRef | CAS |

Cristina, C., Díaz-Torga, G., Baldi, A., Góngora, A., Rubinstein, M., Low, M. J., and Becú-Villalobos, D. (2005). Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice. Endocrinology 146, 2952–2962.
| CrossRef | CAS | PubMed |

Damous, L. L., Silva, S. M., Simões, R. S., Morello, R. J., Carbonel, A. P., Simões, M. J., and Montero, E. F. (2008). Remote ischemic preconditioning on neovascularization and follicle viability on ovary autotransplantation in rats. Transplant. Proc. 40, 861–864.
| CrossRef | CAS | PubMed |

Delvigne, A., and Rozenberg, S. (2002). Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum. Reprod. Update 8, 559–577.
| CrossRef | CAS | PubMed |

Donnez, J., and Dolmans, M. M. (2010). Cryopreservation and transplantation of ovarian tissue. Clin. Obstet. Gynecol. 53, 787–796.
| CrossRef | PubMed |

Duffy, D. M., and Stouffer, R. L. (2002). Follicular administration of a cyclooxygenase inhibitor can prevent oocyte release without alteration of normal luteal function in rhesus monkeys. Hum. Reprod. 17, 2825–2831.
| CrossRef | CAS | PubMed |

Duncan, W. C. (2000). The human corpus luteum: remodelling during luteolysis and maternal recognition of pregnancy. Rev. Reprod. 5, 12–17.
| CrossRef | CAS | PubMed |

Duncan, W. C., van den Driesche, S., and Fraser, H. M. (2008). Inhibition of vascular endothelial growth factor in the primate ovary up-regulates hypoxia-inducible factor-1alpha in the follicle and corpus luteum. Endocrinology 149, 3313–3320.
| CrossRef | CAS | PubMed |

Duncan, W. C., Myers, M., Dickinson, R. E., van den Driesche, S., and Fraser, H. M. (2009). Luteal development and luteolysis in the primate corpus luteum. Anim. Reprod. 6, 34–46.

El Behery, M. M., Diab, A. E., Mowafy, H., Ebrahiem, M. A., and Shehata, A. E. (2011). Effect of laparoscopic ovarian drilling on vascular endothelial growth factor and ovarian stromal blood flow using 3-dimensional power Doppler. Int. J. Gynaecol. Obstet. 112, 119–121.
| CrossRef | CAS | PubMed |

Fauser, B. C., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S., Boivin, J., Petraglia, F., Wijeyeratne, C. N., Norman, R. J., Dunaif, A., Franks, S., Wild, R. A., Dumesic, D., and Barnhart, K. (2012). Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil. Steril. 97, 28–38.
| CrossRef | PubMed |

Fernandez, H., Morin-Surruca, M., Torre, A., Faivre, E., Deffieux, X., and Gervaise, A. (2011). Ovarian drilling for surgical treatment of polycystic ovarian syndrome: a comprehensive review. Reprod. Biomed. Online 22, 556–568.
| CrossRef | PubMed |

Ferrara, N., Frantz, G., LeCouter, J., Dillard-Telm, L., Pham, T., Draksharapu, A., Giordano, T., and Peale, F. (2003). Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Am. J. Pathol. 162, 1881–1893.
| CrossRef | CAS | PubMed |

Franks, S. (2009). Do animal models of polycystic ovary syndrome help to understand its pathogenesis and management? Yes, but their limitations should be recognized. Endocrinology 150, 3983–3985.
| CrossRef | CAS | PubMed |

Fraser, H. M., and Duncan, W. C. (2005). Vascular morphogenesis in the primate ovary. Angiogenesis 8, 101–116.
| CrossRef | PubMed |

Fraser, H. M., and Duncan, W. C. (2009). SRB Reproduction, Fertility and Development Award Lecture 2008. Regulation and manipulation of angiogenesis in the ovary and endometrium. Reprod. Fertil. Dev. 21, 377–392.
| CrossRef | CAS | PubMed |

Fraser, H. M., Bell, J., Wilson, H., Taylor, P. D., Morgan, K., Anderson, R. A., and Duncan, W. C. (2005). Localization and quantification of cyclic changes in the expression of endocrine gland vascular endothelial growth factor in the human corpus luteum. J. Clin. Endocrinol. Metab. 90, 427–434.
| CrossRef | CAS | PubMed |

Fraser, H. M., Wilson, H., Wulff, C., Rudge, J. S., and Wiegand, S. J. (2006). Administration of vascular endothelial growth factor Trap during the ‘post-angiogenic’ period of the luteal phase causes rapid functional luteolysis and selective endothelial cell death in the marmoset. Reproduction 132, 589–600.
| CrossRef | CAS | PubMed |

Fraser, H. M., Morris, K. D., Wiegand, S. J., and Wilson, H. (2010). Inhibition of vascular endothelial growth factor during the postovulatory period prevents pregnancy in the marmoset. Contraception 82, 572–578.
| CrossRef | CAS | PubMed |

Fraser, H. M., Hastings, J. M., Allan, D., Morris, K. D., Rudge, J. S., and Wiegand, S. J. (2012). Inhibition of delta-like ligand 4 induces luteal hypervascularisation followed by functional and structural luteolysis in the primate ovary. Endocrinology 153, 1972–1983.
| CrossRef | CAS | PubMed |

Friedman, O., Orvieto, R., Fisch, B., Felz, C., Freud, E., Ben-Haroush, A., and Abir, R. (2012). Possible improvements in human ovarian grafting by various host and graft treatments. Hum. Reprod. 27, 474–482.
| CrossRef | CAS | PubMed |

Fujii, E. Y., and Nakayama, M. (2010). The measurements of RAGE, VEGF and AGEs in the plasma and follicular fluid of reproductive women: the influence of aging. Fertil. Steril. 94, 694–700.
| CrossRef | CAS | PubMed |

Gaitskell, K., Martinek, I., Bryant, A., Kehoe, S., Nicum, S., and Morrison, J. (2011). Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst. Rev. 7, CD007930.

Gao, M. Z., Zhao, X. M., Sun, Z. G., Hong, Y., Zhao, L. W., and Zhang, H. Q. (2011). Endocrine gland-derived vascular endothelial growth factor concentrations in follicular fluid and serum may predict ovarian hyperstimulation syndrome in women undergoing controlled ovarian hyperstimulation. Fertil. Steril. 95, 673–678.
| CrossRef | CAS | PubMed |

Garside, S. A., Harlow, C. R., Hillier, S. G., Fraser, H. M., and Thomas, F. H. (2010a). Thrombospondin-1 inhibits angiogenesis and promotes follicular atresia in a novel in vitro angiogenesis assay. Endocrinology 151, 1280–1289.
| CrossRef | CAS | PubMed |

Garside, S. A., Henkin, J., Morris, K. D., Norvell, S. M., Thomas, F. H., and Fraser, H. M. (2010b). A thrombospondin-mimetic peptide, ABT-898, suppresses angiogenesis and promotes follicular atresia in pre- and early-antral follicles in vivo. Endocrinology 151, 5905–5915.
| CrossRef | CAS | PubMed |

Gaytan, F., Morales, C., Bellido, C., Aguilar, E., and Sanchez-Criado, J. E. (1997). Role of prolactin in the regulation of macrophages and in the proliferative activity of vascular cells in newly formed and regressing rat corpora lutea. Biol. Reprod. 57, 478–486.
| CrossRef | CAS | PubMed |

Ginther, O. J., Gastal, E. L., Gastal, M. O., and Beg, M. A. (2005). In vivo effects of pregnancy-associated plasma protein-A, activin-A and vascular endothelial growth factor on other follicular-fluid factors during follicle deviation in mares. Reproduction 129, 489–496.
| CrossRef | CAS | PubMed |

Goldhar, A. S., Vonderhaar, B. K., Trott, J. F., and Hovey, R. C. (2005). Prolactin-induced expression of vascular endothelial growth factor via Egr-1. Mol. Cell. Endocrinol. 232, 9–19.
| CrossRef | CAS | PubMed |

Gómez, R., Simón, C., Remohí, J., and Pellicer, A. (2002). Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 143, 4339–4348.
| CrossRef | PubMed |

Gómez, R., Gonzalez-Izquierdo, M., Zimmermann, R. C., Novella-Maestre, E., Alonso-Muriel, I., Sanchez-Criado, J., Remohi, J., Simon, C., and Pellicer, A. (2006). Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 147, 5400–5411.
| CrossRef | PubMed |

Gómez, R., Ferrero, H., Delgado-Rosas, F., Gaytan, M., Morales, C., Zimmermann, R. C., Simón, C., Gaytan, F., and Pellicer, A. (2011). Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment. J. Clin. Endocrinol. Metab. 96, 2484–2492.
| CrossRef | PubMed |

Goodheart, M. J., Ritchie, J. M., Rose, S. L., Fruehauf, J. P., De Young, B. R., and Buller, R. E. (2005). The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin. Cancer Res. 11, 3733–3742.
| CrossRef | CAS | PubMed |

Grosdemouge, I., Bachelot, A., Lucas, A., Baran, N., Kelly, P. A., and Binart, N. (2003). Effects of deletion of the prolactin receptor on ovarian gene expression. Reprod. Biol. Endocrinol. 1, 12.
| CrossRef | PubMed |

Gutman, G., Barak, V., Maslovitz, S., Amit, A., Lessing, J. B., and Geva, E. (2008). Regulation of vascular endothelial growth factor-A and its soluble receptor sFlt-1 by luteinizing hormone in vivo: implication for ovarian follicle angiogenesis. Fertil. Steril. 89, 922–926.
| CrossRef | CAS | PubMed |

Hanahan, D. (1997). Signalling vascular morphogenesis and maintenance. Science 277, 48–50.
| CrossRef | CAS | PubMed |

Hazzard, T. M., Molskness, T. A., Chaffin, C. L., and Stouffer, R. L. (1999). Vascular endothelial growth factor (VEGF) and angiopoietin regulation by gonadotrophin and steroids in macaque granulosa cells during the peri-ovulatory interval. Mol. Hum. Reprod. 5, 1115–1121.
| CrossRef | CAS | PubMed |

Hazzard, T. M., Christenson, L. K., and Stouffer, R. L. (2000). Changes in expression of vascular endothelial growth factor and angiopoietin-1 and -2 in the macaque corpus luteum during the menstrual cycle. Mol. Hum. Reprod. 6, 993–998.
| CrossRef | CAS | PubMed |

Hazzard, T. M., Xu, F., and Stouffer, R. L. (2002). Injection of soluble vascular endothelial growth factor receptor 1 into the preovulatory follicle disrupts ovulation and subsequent luteal function in rhesus monkeys. Biol. Reprod. 67, 1305–1312.
| CrossRef | CAS | PubMed |

Hellström, M., Phng, L. K., Hofmann, J. J., Wallgard, E., Coultas, L., Lindblom, P., Alva, J., Nilsson, A. K., Karlsson, L., Gaiano, N., Yoon, K., Rossant, J., Iruela-Arispe, M. L., Kalen, M., Gerhardt, H., and Betsholtz, C. (2007). Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445, 776–780.
| CrossRef | PubMed |

Henkin, J., and Volpert, O. V. (2011). Therapies using anti-angiogenic peptide mimetics of thrombospondin-1. Expert Opin. Ther. Targets 15, 1369–1386.
| CrossRef | CAS | PubMed |

Hu, W., Lu, C., Dong, H. H., Huang, J., Shen, D. Y., Stone, R. L., Nick, A. M., Shahzad, M. M., Mora, E., Jennings, N. B., Lee, S. J., Roh, J. W., Matsuo, K., Nishimura, M., Goodman, B. W., Jaffe, R. B., Langley, R. R., Deavers, M. T., Lopez-Berestein, G., Coleman, R. L., and Sood, A. K. (2011). Biological roles of the Delta family Notch ligand Dll4 in tumour and endothelial cells in ovarian cancer. Cancer Res. 71, 6030–6039.
| CrossRef | CAS | PubMed |

Huang, Y., Hua, K., Zhou, X., Jin, H., Chen, X., Lu, X., Yu, Y., Zha, X., and Feng, Y. (2008). Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. Cell Res. 18, 780–791.
| CrossRef | CAS | PubMed |

Lawler, J. (2002). Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumour growth. J. Cell. Mol. Med. 6, 1–12.
| CrossRef | CAS | PubMed |

Levit, A., Yarnitzky, T., Wiener, A., Meidan, R., and Niv, M. Y. (2011). Modelling of human prokineticin receptors: interactions with novel small-molecule binders and potential off-target drugs. PLoS ONE 6, e27990.
| CrossRef | CAS | PubMed |

Li, W., Ji, Z. L., Zhuo, G. C., Xu, R. J., Wang, J., and Jiang, H. R. (2010). Effects of a selective cyclooxygenase-1 inhibitor in SKOV-3 ovarian carcinoma xenograft-bearing mice. Med. Oncol. 27, 98–104.
| CrossRef | PubMed |

Li, W., Wang, J., Jiang, H. R., Xu, X. L., Zhang, J., Liu, M. L., and Zhai, L. Y. (2011). Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo. Int. J. Mol. Sci. 12, 668–681.
| CrossRef | CAS | PubMed |

Lobov, I. B., Renard, R. A., Papadopoulos, N., Gale, N. W., Thurston, G., Yancopoulos, G. D., and Wiegand, S. J. (2007). Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc. Natl. Acad. Sci. USA 104, 3219–3224.
| CrossRef | CAS | PubMed |

Malaguarnera, L., Imbesi, R. M., Scuto, A., D’Amico, F., Licata, F., Messina, A., and Sanfilippo, S. (2004). Prolactin increases HO-1 expression and induces VEGF production in human macrophages. J. Cell. Biochem. 93, 197–206.
| CrossRef | CAS | PubMed |

Maldonado-Pérez, D., Evans, J., Denison, F., Millar, R. P., and Jabbour, H. N. (2007). Potential roles of the prokineticins in reproduction. Trends Endocrinol. Metab. 18, 66–72.
| CrossRef | PubMed |

Martelli, A., Bernabò, N., Berardinelli, P., Russo, V., Rinaldi, C., Di Giacinto, O., Mauro, A., and Barboni, B. (2009). Vascular supply as a discriminating factor for pig preantral follicle selection. Reproduction 137, 45–58.
| CrossRef | CAS | PubMed |

Mathur, R., Kailasam, C., and Jenkins, J. (2007). Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome. Hum. Fertil. 10, 75–85.
| CrossRef | CAS |

McFee, R. M., Rozell, T. G., and Cupp, A. S. (2012). The balance of pro-angiogenic and anti-angiogenic VEGFA isoforms regulate follicle development. Cell Tissue Res. , .
| CrossRef | PubMed |

Monnier, J., and Samson, M. (2010). Prokineticins in angiogenesis and cancer. Cancer Lett. 296, 144–149.
| CrossRef | CAS | PubMed |

Monteleone, P., Giovanni Artini, P., Simi, G., Casarosa, E., Cela, V., and Genazzani, A. R. (2008). Follicular fluid VEGF levels directly correlate with perifollicular blood flow in normoresponder patients undergoing IVF. J. Assist. Reprod. Genet. 25, 183–186.
| CrossRef | PubMed |

Oberaigner, W., Minicozzi, P., Bielska-Lasota, M., Allemani, C., de Angelis, R., Mangone, L., and Sant, M. (2012). Survival for ovarian cancer in europe: the across-country variation did not shrink in the past decade. Acta Oncol. , .
| CrossRef | PubMed |

Obermajer, N., Muthuswamy, R., Odunsi, K., Edwards, R. P., and Kalinski, P. (2011). PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 71, 7463–7470.
| CrossRef | CAS | PubMed |

Palomba, S., Falbo, A., Zullo, F., and Orio, F., (2009). Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr. Rev. 30, 1–50.
| CrossRef | CAS | PubMed |

Palomba, S., Falbo, A., Carrillo, L., Villani, M. T., Orio, F., Russo, T., Di Cello, A., Cappiello, F., Capasso, S., Tolino, A., Colao, A., Mastrantonio, P., La Sala, G. B., Zullo, F., Cittadini, E.; , METformin in High Responder Italian Group (2011). Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotrophin-stimulated in vitro fertilisation cycles: a randomised, controlled trial. Fertil. Steril. 96, 1384–1390.
| CrossRef | CAS | PubMed |

Peitsidis, P., and Agrawal, R. (2010). Role of vascular endothelial growth factor in women with PCO and PCOS: a systematic review. Reprod. Biomed. Online 20, 444–452.
| CrossRef | CAS | PubMed |

Pezzuto, A., Ferrari, B., Coppola, F., and Nardelli, G. B. (2010). LH supplementation in down-regulated women undergoing assisted reproduction with baseline low serum LH levels. Gynecol. Endocrinol. 26, 118–124.
| CrossRef | CAS | PubMed |

Pietrowski, D., Szabo, L., Sator, M., Just, A., and Egarter, C. (2012). Ovarian hyperstimulation syndrome is correlated with a reduction of soluble VEGF receptor protein level and a higher amount of VEGF-A. Hum. Reprod. 27, 196–199.
| CrossRef | CAS | PubMed |

Qiu, Y., Seager, M., Osman, A., Castle-Miller, J. S., Bevan, H. S., Tortonese, D. J., Murphy, D., Harper, S. J., Fraser, H. M., Donaldson, L. F., and Bates, D. O. (2012). Ovarian VEGF165b expression regulates follicular development, corpus luteum function and fertility. Reproduction , .
| CrossRef | PubMed |

Quintana, R., Kopcow, L., Marconi, G., Young, E., Yovanovich, C., and Paz, D. A. (2008). Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model. Fertil. Steril. 90, 1511–1516.
| CrossRef | CAS | PubMed |

Rizk, B. (2009). Symposium: update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome. Reprod. Biomed. Online 19, 14–27.
| CrossRef | CAS | PubMed |

Rodewald, M., Herr, D., Fraser, H. M., Hack, G., Kreienberg, R., and Wulff, C. (2007). Regulation of tight-junction proteins occludin and claudin 5 in the primate ovary during the ovulatory cycle and after inhibition of vascular endothelial growth factor. Mol. Hum. Reprod. 13, 781–789.
| CrossRef | CAS | PubMed |

Rodewald, M., Herr, D., Duncan, W. C., Fraser, H. M., Hack, G., Konrad, R., Gagsteiger, F., Kreienberg, R., and Wulff, C. (2009). Molecular mechanisms of ovarian hyperstimulation syndrome: paracrine reduction of endothelial claudin 5 by hCG in vitro is associated with increased endothelial permeability. Hum. Reprod. 24, 1191–1199.
| CrossRef | CAS | PubMed |

Rogosin, S., and Sandler, A. B. (2012). Beyond Bevacizumab: anti-angiogenic agents. Clin. Lung Cancer , .
| CrossRef | PubMed |

Rubatt, J. M., Darcy, K. M., Hutson, A., Bean, S. M., Havrilesky, L. J., Grace, L. A., Berchuck, A., and Secord, A. A. (2009). Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status and angiogenic marker expression: a Gynecologic Oncology Group study. Gynecol. Oncol. 112, 469–474.
| CrossRef | CAS | PubMed |

Sakurai, T., Suzuki, K., Yoshie, M., Hashimoto, K., Tachikawa, E., and Tamura, K. (2011). Stimulation of tube formation mediated through the prostaglandin EP2 receptor in rat luteal endothelial cells. J. Endocrinol. 209, 33–43.
| CrossRef | CAS | PubMed |

Sboros, V., Averkiou, M., Lampaskis, M., Thomas, D. H., Silva, N., Strouthos, C., Docherty, J., and McNeilly, A. S. (2011). Imaging of the ovine corpus luteum microcirculation with contrast ultrasound. Ultrasound Med. Biol. 37, 59–68.
| CrossRef | PubMed |

Seekallu, S. V., Toosi, B. M., and Rawlings, N. C. (2009). LH pulse frequency and the emergence and growth of ovarian antral follicular waves in the ewe during the luteal phase of the oestrous cycle. Reprod. Biol. Endocrinol. 7, 78.
| CrossRef | PubMed |

Shah, D. K., Menon, K. M., Cabrera, L. M., Vahratian, A., Kavoussi, S. K., and Lebovic, D. I. (2010). Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinised granulosa cells in vitro. Fertil. Steril. 93, 2042–2047.
| CrossRef | CAS | PubMed |

Shikanov, A., Zhang, Z., Xu, M., Smith, R. M., Rajan, A., Woodruff, T. K., and Shea, L. D. (2011). Fibrin encapsulation and vascular endothelial growth factor delivery promotes ovarian graft survival in mice. Tissue Eng. Part A 17, 3095–3104.
| CrossRef | CAS | PubMed |

Skaznik-Wikiel, M. E., Sharma, R. K., Selesniemi, K., Lee, H. J., Tilly, J. L., and Falcone, T. (2011). Granulocyte colony-stimulating factor in conjunction with vascular endothelial growth factor maintains primordial follicle numbers in transplanted mouse ovaries. Fertil. Steril. 95, 1405–1409.
| CrossRef | CAS | PubMed |

Stanek, M. B., Borman, S. M., Molskness, T. A., Larson, J. M., Stouffer, R. L., and Patton, P. E. (2007). Insulin and insulin-like growth factor stimulation of vascular endothelial growth factor production by luteinised granulosa cells: comparison between polycystic ovarian syndrome (PCOS) and non-PCOS women. J. Clin. Endocrinol. Metab. 92, 2726–2733.
| CrossRef | CAS | PubMed |

Stocco, C., Telleria, C., and Gibori, G. (2007). The molecular control of corpus luteum formation, function and regression. Endocr. Rev. 28, 117–149.
| CrossRef | CAS | PubMed |

Suchting, S., Freitas, C., le Noble, F., Benedito, R., Breant, C., Duarte, A., and Eichmann, A. (2007). The Notch ligand-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc. Natl. Acad. Sci. USA 104, 3225–3230.
| CrossRef | CAS | PubMed |

Sugino, N., Suzuki, T., Sakata, A., Miwa, I., Asada, H., Taketani, T., Yamagata, Y., and Tamura, H. (2005). Angiogenesis in the human corpus luteum: changes in expression of angiopoietins in the corpus luteum throughout the menstrual cycle and in early pregnancy. J. Clin. Endocrinol. Metab. 90, 6141–6148.
| CrossRef | CAS | PubMed |

Swanton, A., Lighten, A., Granne, I., McVeigh, E., Lavery, S., Trew, G., Talmor, A., Raine-Fenning, N., Jayaprakasan, K., and Child, T. (2011). Do women with ovaries of polycystic morphology without any other features of PCOS benefit from short-term metformin co-treatment during IVF? A double-blind, placebo-controlled, randomised trial. Hum. Reprod. 26, 2178–2184.
| CrossRef | CAS | PubMed |

Tamasi, G., Casolaro, M., Magnani, A., Sega, A., Chiasserini, L., Messori, L., Gabbiani, C., Valiahdi, S. M., Jakupec, M. A., Keppler, B. K., Hursthouse, M. B., and Cini, R. (2010). New platinum–oxicam complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro. J. Inorg. Biochem. 104, 799–814.
| CrossRef | CAS | PubMed |

Tatone, C., Amicarelli, F., Carbone, M. C., Monteleone, P., Caserta, D., Marci, R., Artini, P. G., Piomboni, P., and Focarelli, R. (2008). Cellular and molecular aspects of ovarian follicle ageing. Hum. Reprod. Update 14, 131–142.
| CrossRef | CAS | PubMed |

Teoh, D., and Secord, A. A. (2012). Anti-angiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. Int. J. Gynecol. Cancer 22, 348–359.
| CrossRef | PubMed |

Thierry van Dessel, H. J., Lee, P. D., Faessen, G., Fauser, B. C., and Giudice, L. C. (1999). Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 84, 3030–3035.
| CrossRef | CAS | PubMed |

Thomas, C. M., Boss, E. A., Boonstra, H., van Tienoven, D., Sweep, C. G., and Massuger, L. F. (2008). Gonadotrophins and female sex steroid hormones in cyst fluid and serum from patients with ovarian tumours. Eur. J. Gynaecol. Oncol. 29, 468–472.
| CAS | PubMed |

Tso, L. O., Costello, M. F., Albuquerque, L. E., Andriolo, R. B., and Freitas, V. (2009). Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst. Rev. 15, CD006105.

Uddin, S., Ahmed, M., Hussain, A., Assad, L., Al-Dayel, F., Bavi, P., Al-Kuraya, K. S., and Munkarah, A. (2010). Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int. J. Cancer 126, 382–394.
| CrossRef | CAS | PubMed |

van de Lagemaat, R., Raafs, B. C., van Koppen, C., Timmers, C. M., Mulders, S. M., and Hanssen, R. G. (2011). Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH. Endocrinology 152, 4350–4357.
| CrossRef | CAS | PubMed |

van den Driesche, S., Myers, M., Gay, E., Thong, K. J., and Duncan, W. C. (2008). Human chorionic gonadotrophin up-regulates hypoxia inducible factor-1 alpha in luteinised granulosa cells: implications for the hormonal regulation of vascular endothelial growth factor A in the human corpus luteum. Mol. Hum. Reprod. 14, 455–464.
| CrossRef | CAS | PubMed |

Vardhana, P. A., Julius, M. A., Pollak, S. V., Lustbader, E. G., Trousdale, R. K., and Lustbader, J. W. (2009). A unique human chorionic gonadotrophin antagonist suppresses ovarian hyperstimulation syndrome in rats. Endocrinology 150, 3807–3814.
| CrossRef | CAS | PubMed |

Várnagy, A., Bódis, J., Mánfai, Z., Wilhelm, F., Busznyák, C., and Koppán, M. (2010). Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome. Fertil. Steril. 93, 2281–2284.
| CrossRef | PubMed |

Vikhanskaya, F., Bani, M. R., Borsotti, P., Ghilardi, C., Ceruti, R., Ghisleni, G., Marabese, M., Giavazzi, R., Broggini, M., and Taraboletti, G. (2001). p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumour angiogenesis. Oncogene 20, 7293–7300.
| CrossRef | CAS | PubMed |

Vlahos, N. P., Bugg, E. M., Shamblott, M. J., Phelps, J. Y., Gearhart, J. D., and Zacur, H. A. (2001). Prolactin receptor gene expression and immunolocalisation of the prolactin receptor in human luteinised granulosa cells. Mol. Hum. Reprod. 7, 1033–1038.
| CrossRef | CAS | PubMed |

Wulff, C., Wilson, H., Largue, P., Duncan, W. C., Armstrong, D. G., and Fraser, H. M. (2000). Angiogenesis in the human corpus luteum: localisation and changes in angiopoietins, tie-2 and vascular endothelial growth factor messenger ribonucleic acid. J. Clin. Endocrinol. Metab. 85, 4302–4309.
| CrossRef | CAS | PubMed |

Wulff, C., Wilson, H., Wiegand, S. J., Rudge, J. S., and Fraser, H. M. (2002). Prevention of thecal angiogenesis, antral follicular growth and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology 143, 2797–2807.
| CrossRef | CAS | PubMed |

Xin, B., Yokoyama, Y., Shigeto, T., Futagami, M., and Mizunuma, H. (2007b). Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer 110, 791–800.
| CrossRef | CAS | PubMed |

Xin, B., Yokoyama, Y., Shigeto, T., and Mizunuma, H. (2007a). Anti-tumour effect of non-steroidal anti-inflammatory drugs on human ovarian cancers. Pathol. Oncol. Res. 13, 365–369.
| CrossRef | CAS | PubMed |

Xu, F., and Stouffer, R. L. (2005). Local delivery of angiopoietin-2 into the preovulatory follicle terminates the menstrual cycle in rhesus monkeys. Biol. Reprod. 72, 1352–1358.
| CrossRef | CAS | PubMed |

Yan, M., and Plowman, G. D. (2007). Delta-like 4/Notch signalling and its therapeutic implications. Clin. Cancer Res. 13, 7243–7246.
| CrossRef | CAS | PubMed |

Youssef, M. A., van Wely, M., Hassan, M. A., Al-Inany, H. G., Mochtar, M., Khattab, S., and van der Veen, F. (2010). Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum. Reprod. Update 16, 459–466.
| CrossRef | CAS | PubMed |

Zhang, L., Yang, N., Conejo-Garcia, J. R., Katsaros, D., Mohamed-Hadley, A., Fracchioli, S., Schlienger, K., Toll, A., Levine, B., Rubin, S. C., and Coukos, G. (2003). Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Clin. Cancer Res. 9, 264–272.
| PubMed |